Aspergillus Species and House Dust Mites: Their Allergenicity and Contribution: A Review Article

Document Type : Narrative Review


1 Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

2 Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran


Allergies are pathological manifestations originating from a trigger-sensitized immune system. Aspergillus species have been reported to be one of the important inhalant allergens in different geographical regions of the world. House dust mite (HDM) allergens play a major role in causing allergic diseases. The emerging literature indicates the allergenicity and contribution of Aspergillus species and HDMs. Allergies erupt when innocuous foreign components are confused as foes by the immune surveillance. The incidence of fungal sensitization in patients with allergic respiratory diseases has been reported from 2.3% to even 80% in various studies worldwide. Human skin scales provide food for both mites and fungi. Fungi may either constitute a food supplement for mites or may have an indirect effect by decomposing human dander, thus making it more accessible for HDMs. There is a mutual relationship between fungi and HDMs. In addition to avoid exposure to an allergen as a secondary or tertiary preventive strategy, which is often not sufficiently effective against domestic mites, the treatment of mite allergy is mainly based on allergen-specific immunotherapy (AIT). Treatment with azole antifungal drugs in patients with severe asthma is effective and improves patient quality of life.


  1. Baird FJ, Lopata AL. The dichotomy of pathogens and allergens in vaccination approaches. Front Microbiol. 2014;5:365. doi:10.3389/fmicb.2014.00365.
  2. Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357(9270):1777-1789. doi:10.1016/S0140-6736(00)04904-7.
  3. Parronchi P, Brugnolo F, Sampognaro S, Maggi E. Genetic and environmental factors contributing to the onset of allergic disorders. Int Arch Allergy Immunol. 2000;121(1):2-9. doi:10.1159/000024291.
  4. Sheffer A, Bartal M, Bousquet J. Global strategy for asthma management and prevention. WHO Workshop Report Publication; 1995.
  5. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8-160. doi:10.1111/j.1398-9995.2007.01620.x.
  6. Koppelman GH. Gene-environment interaction in allergic disease: more questions, more answers? J Allergy Clin Immunol. 2007;120(6):1266-1268. doi:10.1016/j.jaci.2007.10.007.
  7. Dave ND, Xiang L, Rehm KE, Marshall GD Jr. Stress and allergic diseases. Immunol Allergy Clin North Am. 2011;31(1):55-68. doi:10.1016/j.iac.2010.09.009.
  8. Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73-85. doi:10.1016/j.aller.2012.03.001.
  9. Huang SK, Zhang Q, Qiu Z, Chung KF. Mechanistic impact of outdoor air pollution on asthma and allergic diseases. J Thorac Dis. 2015;7(1):23-33. doi:10.3978/j.issn.2072-1439.2014.12.13.
  10. Simon-Nobbe B, Denk U, Poll V, Rid R, Breitenbach M. The spectrum of fungal allergy. Int Arch Allergy Immunol. 2008;145(1):58-86. doi:10.1159/000107578.
  11. Zureik M, Neukirch C, Leynaert B, Liard R, Bousquet J, Neukirch F. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ. 2002;325(7361):411-414. doi:10.1136/bmj.325.7361.411.
  12. Platts-Mills TA, Hayden ML, Chapman MD, Wilkins SR. Seasonal variation in dust mite and grass-pollen allergens in dust from the houses of patients with asthma. J Allergy Clin Immunol. 1987;79(5):781-791. doi:10.1016/0091-6749(87)90211-9.
  13. van der Heide S, de Monchy JG, de Vries K, Bruggink TM, Kauffman HF. Seasonal variation in airway hyperresponsiveness and natural exposure to house dust mite allergens in patients with asthma. J Allergy Clin Immunol. 1994;93(2):470-475. doi:10.1016/0091-6749(94)90356-5.
  14. Ezeamuzie CI, Al-Ali S, Khan M, et al. IgE-mediated sensitization to mould allergens among patients with allergic respiratory diseases in a desert environment. Int Arch Allergy Immunol. 2000;121(4):300-307. doi:10.1159/000024343.
  15. Mari A, Schneider P, Wally V, Breitenbach M, Simon-Nobbe B. Sensitization to fungi: epidemiology, comparative skin tests, and IgE reactivity of fungal extracts. Clin Exp Allergy. 2003;33(10):1429- 1438. doi:10.1046/j.1365-2222.2003.01783.x.
  16. Gioulekas D, Damialis A, Papakosta D, Spieksma F, Giouleka P, Patakas D. Allergenic fungi spore records (15 years) and sensitization in patients with respiratory allergy in Thessaloniki- Greece. J Investig Allergol Clin Immunol. 2004;14(3):225-231.
  17. D’Amato G, Chatzigeorgiou G, Corsico R, et al. Evaluation of the prevalence of skin prick test positivity to Alternaria and Cladosporium in patients with suspected respiratory allergy. A European multicenter study promoted by the Subcommittee on Aerobiology and Environmental Aspects of Inhalant Allergens of the European Academy of Allergology and Clinical Immunology. Allergy. 1997;52(7):711-716. doi:10.1111/j.1398-9995.1997.tb01227.x.
  18. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med. 1990;323(8):502- 507. doi:10.1056/NEJM199008233230802.
  19. Sears MR, Herbison GP, Holdaway MD, Hewitt CJ, Flannery EM, Silva PA. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. Clin Exp Allergy. 1989;19(4):419-424. doi:10.1111/j.1365-2222.1989.tb02408.x.
  20. Lam HT, Ekerljung L, Bjerg A, Van TTN, Lundback B, Ronmark E. Sensitization to airborne allergens among adults and its impact on allergic symptoms: a population survey in northern Vietnam. Clin Transl Allergy. 2014;4(1):6. doi:10.1186/2045-7022-4-6.
  21. Macan J, Plavec D, Kanceljak B, Milkovic-Kraus S. Exposure levels and skin reactivity to German cockroach (Blattella germanica) in Croatia. Croat Med J. 2003;44(6):756-760.
  22. Tungtrongchitr A, Sookrung N, Munkong N, et al. The levels of cockroach allergen in relation to cockroach species and allergic diseases in Thai patients. Asian Pac J Allergy Immunol. 2004;22(2- 3):115-121.
  23. Tobias KR, Ferriani VP, Chapman MD, Arruda LK. Exposure to indoor allergens in homes of patients with asthma and/or rhinitis in southeast Brazil: effect of mattress and pillow covers on mite allergen levels. Int Arch Allergy Immunol. 2004;133(4):365-370. doi:10.1159/000077356.
  24. Liccardi G, Baldi G, Ciccarelli A, et al. Sensitization to cockroach allergens in the urban atopic populations living in Campania district (southern Italy). A multicenter study. Eur Ann Allergy Clin Immunol. 2014;46(1):12-16.
  25. Sun BQ, Lai XX, Gjesing B, Spangfort MD, Zhong NS. Prevalence of sensitivity to cockroach allergens and IgE cross-reactivity between cockroach and house dust mite allergens in Chinese patients with allergic rhinitis and asthma. Chin Med J (Engl). 2010;123(24):3540- 3544. doi:10.3760/cma.j.issn.0366-6999.2010.24.007.
  26. Salazar F, Ghaemmaghami AM. Allergen recognition by innate immune cells: critical role of dendritic and epithelial cells. Front Immunol. 2013;4:356. doi:10.3389/fimmu.2013.00356.
  27. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704. doi:10.1038/nm.2755.
  28. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S73-80. doi:10.1016/j.jaci.2009.11.017.
  29. Saggini A, Maccauro G, Tripodi D, et al. Allergic inflammation: role of cytokines with special emphasis on IL-4. Int J Immunopathol Pharmacol. 2011;24(2):305-311. doi:10.1177/039463201102400204.
  30. Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease. 5th ed. New York: Garland Science; 2001:12-3.
  31. Arlian LG. Arthropod allergens and human health. Annu Rev Entomol. 2002;47:395-433. doi:10.1146/annurev.ento.47.091201.145224.
  32. Kim CW, Hong CS. Allergy to miscellaneous household arthropods. Protein Pept Lett. 2007;14(10):982-991. doi:10.2174/092986607782541079.
  33. Davila I, Valero A, Entrenas LM, Valveny N, Herraez L. Relationship between serum total IgE and disease severity in patients with allergic asthma in Spain. J Investig Allergol Clin Immunol. 2015;25(2):120-127.
  34. Custovic A, Simpson A. The role of inhalant allergens in allergic airways disease. J Investig Allergol Clin Immunol. 2012;22(6):393- 401; qiuz follow 401.
  35. Erwin EA, Ronmark E, Wickens K, et al. Contribution of dust mite and cat specific IgE to total IgE: relevance to asthma prevalence. J Allergy Clin Immunol. 2007;119(2):359-365. doi:10.1016/j.jaci.2006.12.648.
  36. Custovic A, Sonntag HJ, Buchan IE, Belgrave D, Simpson A, Prosperi MCF. Evolution pathways of IgE responses to grass and mite allergens throughout childhood. J Allergy Clin Immunol. 2015;136(6):1645-1652.e1648. doi:10.1016/j.jaci.2015.03.041.
  37. Resch Y, Michel S, Kabesch M, Lupinek C, Valenta R, Vrtala S. Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children. J Allergy Clin Immunol. 2015;136(4):1083-1091. doi:10.1016/j.jaci.2015.03.024.
  38. Vidal C, Lojo S, Juangorena M, Gonzalez-Quintela A. Association between asthma and sensitization to allergens of Dermatophagoides pteronyssinus. J Investig Allergol Clin Immunol. 2016;26(5):304- 309. doi:10.18176/jiaci.0048.
  39. Strong P, Clark H, Reid K. Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy. Clin Exp Allergy. 2002;32(12):1794- 1800. doi:10.1046/j.1365-2222.2002.01551.x.
  40. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore). 2000;79(4):250- 260. doi:10.1097/00005792-200007000-00006.
  41. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990;12(6):1147-1201. doi:10.1093/clinids/12.6.1147.
  42. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32(3):358- 366. doi:10.1086/318483.
  43. Fang Z, Ouyang Z, Hu L, Wang X, Zheng H, Lin X. Culturable airborne fungi in outdoor environments in Beijing, China. Sci Total Environ. 2005;350(1-3):47-58. doi:10.1016/j.scitotenv.2005.01.032.
  44. Segvic Klaric M, Pepeljnjak S. A year-round aeromycological study in Zagreb area, Croatia. Ann Agric Environ Med. 2006;13(1):55- 64.
  45. Wu YH, Chan CC, Rao CY, et al. Characteristics, determinants, and spatial variations of ambient fungal levels in the subtropical Taipei metropolis. Atmos Environ. 2007;41(12):2500-2509. doi:10.1016/j.atmosenv.2006.11.035.
  46. O’Gorman CM, Fuller HT. Prevalence of culturable airborne spores of selected allergenic and pathogenic fungi in outdoor air. Atmos Environ. 2008;42(18):4355-4368. doi:10.1016/j.atmosenv.2008.01.009.
  47. Sharma D, Dutta BK, Singh AB, Shome BR. Aerobiological, biochemical and immunological studies on some of the dominant Aspergillus species of South Assam (India). Aerobiologia. 2007;23(3):201. doi:10.1007/s10453-007-9064-0.
  48. Crameri R, Garbani M, Rhyner C, Huitema C. Fungi: the neglected allergenic sources. Allergy. 2014;69(2):176-185. doi:10.1111/all.12325.
  49. Aggarwal S, Chhabra SK, Saxena RK, Agarwal MK. Heterogeneity of immune responses to various Aspergillus species in patients with allergic respiratory diseases. Indian J Chest Dis Allied Sci. 2000;42(4):249-258.
  50. Horner WE, Helbling A, Salvaggio JE, Lehrer SB. Fungal allergens. Clin Microbiol Rev. 1995;8(2):161-179. doi:10.1128/CMR.8.2.161.
  51. Kurup VP, Banerjee B. Fungal allergens and peptide epitopes. Peptides. 2000;21(4):589-599. doi:10.1016/S0196-9781(00)00181-9.
  52. Crameri R, Zeller S, Glaser AG, Vilhelmsson M, Rhyner C. Cross-reactivity among fungal allergens: a clinically relevant phenomenon? Mycoses. 2009;52(2):99-106. doi:10.1111/j.1439-0507.2008.01644.x.
  1. Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013;51(4):361-370. doi:10.3109/13693786.2012.738312.
  2. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70(3):270-277. doi:10.1136/thoraxjnl-2014-206291.
  3. Van Asselt L. Interactions between domestic mites and fungi. Indoor Built Environ. 1999;8(4):216-220. doi:10.1159/000024644.
  4. Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev. 2011;75(2):213-267. doi:10.1128/MMBR.00045-10.
  5. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272-279. doi:10.1016/S0966-842X(03)00117-3.
  6. Al-Shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW. Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis. 2013;57(6):828-835. doi:10.1093/cid/cit411.
  7. Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61(10):1558-1565. doi:10.1093/cid/civ571.
  8. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-360. doi:10.1086/525258.
  9. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106(8):2641-2645. doi:10.1182/blood-2005-02-0733.
  10. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356(14):1481-1483. doi 10.1056/NEJMc061720.
  11. van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis. 2011;17(10):1846- 1854. doi:10.3201/eid1710.110226.
  12. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15(7):1068-1076. doi:10.3201/eid1507.090043.
  13. Arendrup MC, Mavridou E, Mortensen KL, et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One. 2010;5(4):e10080. doi:10.1371/journal.pone.0010080.
  14. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2012;67(2):362-366. doi: 10.1093/jac/dkr443.
  15. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother. 2011;55(9):4465-4468. doi:10.1128/AAC.00185-11.
  16. Matsuse H, Fukushima C, Fukahori S, et al. Differential effects of dexamethasone and itraconazole on Aspergillus fumigatus-exacerbated allergic airway inflammation in a murine model of mite-sensitized asthma. Respiration. 2013;85(5):429-435. doi:10.1159/000345861.
  17. Arshad SH. Does exposure to indoor allergens contribute to the development of asthma and allergy? Curr Allergy Asthma Rep. 2010;10(1):49-55. doi:10.1007/s11882-009-0082-6.
  18. Portnoy J, Chew GL, Phipatanakul W, et al. Environmental assessment and exposure reduction of cockroaches: a practice parameter. J Allergy Clin Immunol. 2013;132(4):802-808.e801- 825. doi:10.1016/j.jaci.2013.04.061.
  19. New TR. Matthew J. Colloff: Dust mites. J Insect Conserv. 2009;13(6):677-8. doi:10.1007/s10841-009-9234-1.
  20. Adkinson NF Jr, Bochner BS, Burks AW, et al. Middleton’s allergy: principles and practice. Elsevier Health Sciences; 2013.
  21. Gregory LG, Lloyd CM. Orchestrating house dust mite-associated allergy in the lung. Trends Immunol. 2011;32(9):402-411. doi:10.1016/
  22. Baxi SN, Phipatanakul W. The role of allergen exposure and avoidance in asthma. Adolesc Med State Art Rev. 2010;21(1):57- 71, viii-ix.
  23. Mosbech H. House dust mite allergy. Allergy. 1985;40(2):81-91. doi:10.1111/j.1398-9995.1985.tb02665.x.
  24. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-476. doi:10.1016/j.jaci.2010.06.047.
  25. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol. 2013;132(6):1322-1336. doi:10.1016/j.jaci.2013.09.004.
  26. An S, Shen C, Liu X, et al. Alpha-actinin is a new type of house dust mite allergen. PLoS One. 2013;8(12):e81377. doi:10.1371/journal.pone.0081377.
  27. Abramson SL, Turner-Henson A, Anderson L, et al. Allergens in school settings: results of environmental assessments in 3 city school systems. J Sch Health. 2006;76(6):246-249. doi:10.1111/j.1746-1561.2006.00105.x.
  28. de Saint Georges-Gridelet D. Vitamin requirements of the European house dust mite, Dermatophagoides pteronyssinus (Acari: Pyroglyphidae), in relation to its fungal association. J Med Entomol. 1987;24(4):408-411. doi:10.1093/jmedent/24.4.408.
  29. Custovic A, Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy. 2005;60(9):1112-1115. doi:10.1111/j.1398-9995.2005.00934.x.
  30. Nelson HS. Update on house dust mite immunotherapy: are more studies needed? Curr Opin Allergy Clin Immunol. 2014;14(6):542- 548. doi:10.1097/ACI.0000000000000104.
  31. Calderon MA, Demoly P, Gerth van Wijk R, et al. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy. 2012;2(1):20. doi:10.1186/2045-7022-2-20.
  32. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558-562. doi:10.1016/S0091-6749(98)70271-4.
  33. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010(8):Cd001186. doi:10.1002/14651858.CD001186.pub2.
  34. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009;64(11):1570- 1579. doi:10.1111/j.1398-9995.2009.02129.x.
  35. Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13(11):1543-1556. doi:10.1517/14712598.2013.844226.
  36. Larenas-Linnemann D, Michels A, Dinger H, et al. Allergen sensitization linked to climate and age, not to intermittent-persistent rhinitis in a cross-sectional cohort study in the (sub) tropics. Clin Transl Allergy. 2014;4:20. doi:10.1186/2045-7022-4-20.
  37. Nurmatov U, van Schayck CP, Hurwitz B, Sheikh A. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. Allergy. 2012;67(2):158- 165. doi:10.1111/j.1398-9995.2011.02752.x.
  38. Wright LS, Phipatanakul W. Environmental remediation in the treatment of allergy and asthma: latest updates. Curr Allergy Asthma Rep. 2014;14(3):419. doi:10.1007/s11882-014-0419-7.
  39. Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med. 2004;351(11):1068-1080. doi:10.1056/NEJMoa032097.
  40. Krieger J, Jacobs DE, Ashley PJ, et al. Housing interventions and control of asthma-related indoor biologic agents: a review of the evidence. J Public Health Manag Pract. 2010;16(5 Suppl):S11-20. doi:10.1097/PHH.0b013e3181ddcbd9.